Colorectal Cancer | Specialty

RAS Mutations Ready for Prime Time in mCRC

June 12th 2014

A multitude of studies presented over the course of the past year have emphasized the importance of broader RAS mutational analyses outside of traditional KRAS testing for patients with metastatic colorectal cancer.

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Dr. Bendell Discusses Two Studies in BRAF-Mutated CRC

June 2nd 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses two studies in BRAF-mutated colorectal cancer.

Survival Comparable With Bevacizumab, Cetuximab in mCRC

June 1st 2014

Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with KRAS wild-type metastatic colorectal cancer

FDA Approves Frontline Panitumumab for KRAS Wild-type mCRC

May 23rd 2014

The FDA has expanded the approval of panitumumab to include the frontline treatment of patients with KRAS wild-type mCRC in combination with chemotherapy.

Studies Link Higher Vitamin D Levels With Improved Cancer Prognosis

May 23rd 2014

Two recently published clinical studies demonstrated a strong association between higher levels of vitamin D and improved outcomes among patients with various cancers.

After Colorectal Cancer Spreads, Additional Imaging Adds Little Benefit

May 20th 2014

For patients whose colorectal cancer has spread to the liver, and confirmed by computed tomography (CT), further imaging scans before surgery added little benefit when compared to patients who did not undergo further imaging.

Dr. Bendell on a Study of Onartuzumab Plus Bevacizumab for mCRC

May 13th 2014

Johanna Bendell, MD, discusses the rationale of a phase II trial looking at onartuzumab (MetMAb) and bevacizumab for patients with metastatic colorectal cancer (mCRC).

TAS-102 Extends Survival in Heavily Pretreated Colorectal Cancer

May 12th 2014

Treatment with the investigational oral agent TAS-102 significantly improved overall survival in a phase III trial for patients with heavily pretreated metastatic colorectal cancer.

FDA Panel Unanimously Recommends New DNA Stool Test

March 27th 2014

The FDA's Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

FDA Panel Narrowly Supports New CRC Blood Test

March 27th 2014

The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA's Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test's benefits outweigh its risks

Dr. Bordonaro on the Treatment of Advanced CRC

March 13th 2014

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses treatment options for patients with colorectal cancer who fail on oxaliplatin- and irinotecan-based chemotherapy.

Dr. Peeters on the Future of Colorectal Cancer

March 11th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.

Integrating Genetic Counseling Into an Oncology Practice Can Benefit High-Risk Families

February 26th 2014

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

Final Thoughts on the Treatment of mCRC

February 26th 2014

Panitumumab, Regorafenib, and Ziv-aflibercept in mCRC

February 26th 2014

Third-Line Treatment Options for mCRC

February 26th 2014

First- and Second-Line Treatment of mCRC in Specific Populations

February 26th 2014

Current Trends in the Treatment of CRC

February 26th 2014

Tumor Profiling in Patients With mCRC

February 26th 2014